controls or in the total number of days in hospital (IDUs: median 23, range 1–123; controls: median 27, range 2–217). Three of the IDUs claimed to be HIV positive at admission but were found to be HIV negative when tested: three others were known to be HIV negative and were admitted for treatment of injection site abscesses. Only one control patient was HIV negative: he had been admitted for source isolation at a time when his HIV status was unknown. Karnofsky scores were estimated for each patient at the time of admission, and used to calculate a mean score per patient: the scores were significantly higher in IDUs (IDUs: 58.6, SD 21.5, controls: 46.5, SD 14.2, p = 0.005), suggesting that they were less unwell. The IDUs had a total of 81 inpatient episodes, 29 of which were with an AIDS-defining illness (using the 1987 CDC criteria), compared with 90 inpatient episodes for controls, 65 of which were with an AIDS-defining illness (χ² = 21.4, p < 0.001). All 13 IDUs who were on legal opiate prescriptions were prescribed methadone on the ward, as were seven of the 13 illegal opiate users.

Behavioural problems were recorded in the medical or nursing notes more often for IDUs than controls (16 incidents in 81 admissions for IDUs, four incidents in 90 admissions for controls, χ² = 8.2, p = 0.04). Recorded incidents included use of non-prescribed drugs, serious non-compliance with treatment and physical or verbal aggression. The IDUs had more unplanned discharges than controls (17 out of 81 admissions vs four out of 90 admissions, χ² = 9.3, p = 0.002). Amongst current IDUs, there was no difference in the number of recorded behavioural problems in those who were or were not prescribed methadone on the ward, or in those who were or were not receiving legal opiate prescriptions at the time of admission. However, behavioural problems were recorded more often in current opiate users compared with former users (15 incidents out of 60 admissions in current users vs 1 out of 21 in former users: χ² = 2.8, p = 0.037).

 Substance misuse on the ward was documented in nine out of 81 admissions for IDUs: there were no recorded episodes in the control group (χ² = 8.4, p = 0.0009). Amongst current IDUs, there was no difference in episodes of substance misuse between those receiving methadone on the ward and those who were not, but there were fewer episodes in those receiving prescribed opiates at the time of admission (one incident in 27 admissions vs eight in 33, χ² = 4.9, p = 0.02). No episodes were recorded in former IDUs.

Our data show no difference between IDUs and controls in the frequency or length of admissions: however, the IDUs were less unwell on admission. This may reflect poorer social circumstances (such as homelessness), inability to cope at home when unwell and difficulties complying with out-patient treatment, as was demonstrated by a study in France. Three IDUs were admitted to the unit by falsely claiming to be HIV positive, possibly because it may be easier for HIV positive IDUs to obtain opiates from medical services.

Drug users have a reputation for behaving badly during medical admissions, but we found relatively few recorded incidents, although they were more frequent in IDUs than controls. However, very few problems were noted in the group of former IDUs. Active drug users on HIV inpatient units are likely to need substantial psychosocial input. Nursing and medical staff may need training in dealing with difficult behaviour, and policies for prescription of replacement opiates may be helpful. To avoid unnecessary admission, outpatient HIV services need to be flexible and designed to accommodate drug users as well as non drug users. A liaison service, such as described by Orgel, provided by an addiction specialist could also improve care.

Address for correspondence: Dr Emily JL Finch, Addiction Research Unit, National Addiction Centre, Addiction Sciences Building, 4 Windsor Walk, London SE5 8AF, UK.

Assessment of contraceptive choice in HIV seropositive women

Condoms have proved impermeable in vitro to the human immunodeficiency virus (HIV) and when used consistently in HIV discordant couples have been associated with low seroconversion rates. They have been widely promoted as a means of reducing both HIV transmission and other sexually transmitted diseases whilst affording protection against an unwanted pregnancy. However, it is well recognised that there is a higher conception or failure rate with condoms than certain non barrier methods and fertility rates in HIV infected women are not significantly different from comparable non infected women. Little is known about the factors influencing HIV positive women to request contraceptives additional to condoms.

All HIV seropositive women attending our unit receive contraceptive counselling as part
of their standard medical care. In addition, referrals may be made to a family planning clinic (FPC) held on the same site run by doctors experienced in both family planning and the care of patients with HIV disease. Ten HIV seropositive women attending the on site FPC were interviewed and the reasons for their contraceptive choice ascertained.

The women were aged 21–35 years and originated from Europe (5), Africa (3), South America (1) and the Caribbean (1). Two had advanced symptomatic HIV disease (Centres for Disease Control class IV, CDCIV). All had regular sexual partners of whom six were HIV seropositive and four were of unknown serostatus.

All women wished to continue with condoms as a barrier method of contraception and as protection against HIV transmission. Three women wished to continue with condoms alone but also wished to use the female condom (Femidom), including two women whose partners were having particular difficulty complying with the use of male condoms.

Seven were concerned about the risk of pregnancy and this was the main reason for requesting a second “double” contraceptive method additional to condoms. Six women chose hormonal contraception, two women the progestogen only contraceptive pill (POP), three women an injectable progestogen (IP), one woman the combined oral contraceptive pill (COCP). One woman chose to continue with an intrauterine contraceptive device (IUCD). Their contraceptive choice was based on previous experience and satisfaction with a method (2) or dissatisfaction and a desire to try a new method (8) (table).

An additional influencing factor in those choosing an injectable progestogen was the suppression of menstruation which was regarded as a reminder of their fertility and sorrow at their decision not to conceive. In this sub-group one woman later requested sterilisation, after separating from her partner, as she feared a second child with a different father might be separated from his sibling when she died.

It is essential that any additional contraception supplied does not facilitate the transmission of HIV, worsen immunosuppression, hasten the development of the acquired immunodeficiency syndrome (AIDS) or lead to the abandonment of condoms.

Contraceptive discussions must continue to promote the use of condoms and we routinely recommend the use of male condoms impregnated with nonoxynol-9 spermicide. However, in couples where male condoms are not being used the female condom under the woman’s control may be an alternative, as in vitro data, albeit limited, have shown no HIV leakage across the polyurethane sheath.3

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Partner’s HIV status</th>
<th>Parity</th>
<th>Contraception Prior to FPC</th>
<th>Outcome at 1st FPC</th>
<th>Post FPC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Positive AIDS</td>
<td>0</td>
<td>COCP POP D</td>
<td>Satisfied</td>
<td>MC</td>
</tr>
<tr>
<td>2</td>
<td>Positive</td>
<td>1 C</td>
<td>COCP POP IP IUCD</td>
<td>Nausea Non compliant</td>
<td>MC</td>
</tr>
<tr>
<td>3</td>
<td>Not known</td>
<td>2 TOP</td>
<td>COCP POP D</td>
<td>Breast enlargement</td>
<td>MC</td>
</tr>
<tr>
<td>4</td>
<td>Not known</td>
<td>1 C</td>
<td>COCP POP D</td>
<td>Irregular menses</td>
<td>MC</td>
</tr>
<tr>
<td>5</td>
<td>Positive</td>
<td>1 C</td>
<td>COCP POP D</td>
<td>Non compliant</td>
<td>M</td>
</tr>
<tr>
<td>6</td>
<td>Not known</td>
<td>0</td>
<td>COCP POP D</td>
<td>Breast pain</td>
<td>MC</td>
</tr>
<tr>
<td>7</td>
<td>Not known</td>
<td>2 C</td>
<td>MC D</td>
<td>Inconsistent</td>
<td>Alternating FC/MC</td>
</tr>
<tr>
<td>8</td>
<td>Positive</td>
<td>1 TOP</td>
<td>MC D</td>
<td>Non compliant</td>
<td>Alternating FC/MC</td>
</tr>
<tr>
<td>9</td>
<td>Positive</td>
<td>1 TOP*</td>
<td>UCDC POP IP D</td>
<td>Usually compliant</td>
<td>Inconsistent FC/MC</td>
</tr>
<tr>
<td>10</td>
<td>Positive</td>
<td>1 TOP</td>
<td>IUCD POP IP D</td>
<td>Satisfied</td>
<td>IUCD</td>
</tr>
</tbody>
</table>

IUCD — Intrauterine contraceptive device. COCP — Combined oral contraceptive pill. POP — Progestogen only pill. IP — Injectable progestogen. *After HIV diagnosis.

There appears to be no conclusive evidence to avoid hormonal contraception in HIV seropositive women. On balance, based on immune responses, it may be preferable to consider a progestogen-only pill or an injectable progestogen. An IUCD should be avoided in HIV seropositive women if possible, although we were unable to do so in one patient as all other methods were unacceptable.

We advocate that all HIV seropositive women should have easily accessible contraceptive advice. It is important to realise that although fear of pregnancy may be the prime reason for requesting a second contraceptive method other influences may be present.

E M CARLIN
J M RUSSELL
F C BOAG
St Stephen's Clinic,
Chelsea and Westminster Hospital,
London SW10 9NY, UK

Accepted for publication: 12 August 1994.

The use of barrier contraceptives in Denmark during the AIDS epidemic

In the absence of a cure or vaccine for AIDS, changing sexual behaviour remains the only strategy available to those, who are concerned with this aspect in public health campaigns. Since 1985 the Danish health authorities have given high priority to educational campaigns for prevention of HIV infection in the general population. As a way of controlling the spread of the infection this public information has focused on the use of barrier contraceptives especially condoms for casual sexual intercourse. Less emphasis has been put on reducing the risk of HIV infection by having fewer sexual partners.

Data from Denmark indicate a substantial reduction in the prevalence of major STDs, syphilis, gonorrhoea and hepatitis B since the mid-1980s. In a major STD clinic in Copenhagen a decrease was also noted in the prevalence of chlamydia infections, whereas no consistent changes were detectable in genital warts and genital herpes.

As a result one should expect a general increase in the use of condoms in Denmark since 1984. A figure of the total national use of condoms per year is for obvious reasons not available. In Denmark, the Medicines Department, National Board of Health approves all batches of sold condoms. Each batch contains 72,000 condoms or less. From 1984 to 1993 we have for each year collected the numbers of approved condoms in Denmark (table). The total number of accepted condoms presumably reflects the number of sold or handed out condoms. In addition the number of sanctioned diaphragms each year from 1984 to 1993 are shown in the table.

The table shows that a slight increase in the number of approved condoms occurred from 10–11 millions in 1984–85 to 13–14 millions in 1990–93. In one single year (1988) more than 19 million condoms were accepted for sale. A steady but substantial decrease was noticed in approved diaphragms.

Recently published data have indicated an increased use of condoms during the AIDS epidemic among Danish adolescents and among females attending an STD clinic. The same trend was detected among US college women. This combined with the fact that sexual behaviour among heterosexuals has not changed in recent years should as a consequence result in a marked increase in the number of sold condoms. Although increased use of condoms has taken place, consistent use of condoms is rarely seen.

An explanation for the observed decrease in STDs in Denmark is probably complex. Several factors may contribute, such as reduced promiscuity among homosexual males, increased use of condoms in high-risk individuals (homosexual males and heterosexuals) and female condom use in some groups of heterosexuals and to a certain degree an increased use of condoms in the general population.

CARNSTEN SAND PETERSEN
KAARE WEISMANN
Department of Dermatology,
Bispebjerg Hospital, Bispebjerg Bakke 23,
DK 2450 Copenhagen NV, Denmark

Address correspondence to: Dr C S Petersen.

The total number of approved condoms and diaphragms in Denmark from 1984 to 1993

<table>
<thead>
<tr>
<th>Year</th>
<th>Condoms</th>
<th>Diaphragms</th>
</tr>
</thead>
<tbody>
<tr>
<td>1984</td>
<td>11-4</td>
<td>15012</td>
</tr>
<tr>
<td>1985</td>
<td>10-8</td>
<td>11829</td>
</tr>
<tr>
<td>1986</td>
<td>13-5</td>
<td>18916</td>
</tr>
<tr>
<td>1987</td>
<td>13-6</td>
<td>12289</td>
</tr>
<tr>
<td>1988</td>
<td>10-3</td>
<td>9137</td>
</tr>
<tr>
<td>1989</td>
<td>12-7</td>
<td>10364</td>
</tr>
<tr>
<td>1990</td>
<td>13-1</td>
<td>12252</td>
</tr>
<tr>
<td>1991</td>
<td>13-0</td>
<td>7867</td>
</tr>
<tr>
<td>1992</td>
<td>13-0</td>
<td>6254</td>
</tr>
<tr>
<td>1993</td>
<td>14-7</td>
<td>1712</td>
</tr>
</tbody>
</table>

Assessment of contraceptive choice in HIV seropositive women.

E M Carlin, J M Russell and F C Boag

Genitourin Med 1995 71: 54-56
doi: 10.1136/sti.71.1.54

Updated information and services can be found at:
http://sti.bmj.com/content/71/1/54.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/